nct_id: NCT05541822
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2022-09-15'
study_start_date: '2023-01-17'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Vabametkib'
  - drug_name: 'Drug: Lazertinib'
long_title: A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to
  Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401
  in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition
  Factor (c-MET) Dysregulation
last_updated: '2025-05-22'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Abion Inc
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 178
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- "1. Male or female \u2265 18 years of age or designated age of majority according\
  \ to the regulatory authorities, whichever is higher."
- 2. Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1.
- 3. Have a life expectancy of at least 3 months.
- '4. Diagnosis:'
- 1. must have histologically or cytologically confirmed NSCLC, advanced, recurrent,
  or metastatic,
- '2. For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment.
  \[local testing is accepted for eligibility; all patients will have confirmation
  by central laboratory, but this result is not necessary for eligibility; local molecular
  pathology result will suffice\]. This testing can be from archival or fresh tissue
  sample and/or blood specimen; any sample, any test positive subjects are eligible.'
- '3. For Cohort 2:'
- '* Non-squamous histology (confirmed by histology or cytology)'
- '* EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected
  by an FDA-approved or other validated test in a CLIA certified laboratory (sites
  in the US) or an accredited local laboratory (sites outside of the US) in accordance
  with site standard of care. (Note: A copy of the test report documenting the EGFR
  mutation must be included in the participant records and it must be reviewed by
  the Medical monitor.)'
- '* Radiological documentation of disease progression while on continuous treatment
  with the 1st line 3rd generation EGFR-TKI'
- '* Prior objective clinical benefit defined by either partial or complete radiological
  response, or durable SD (SD should last \> 6 months) from the 1st line 3rd generation
  EGFR-TKI'
- "* Interval between documentation of radiological progression of disease on the\
  \ 1st line 3rd generation EGFR TKI and first dose of study drug should be \u2264\
  \ 60 days"
- "* MET amplification or overexpression from tumor sample collected following progression\
  \ on 1st line 3rd generation EGFR-TKI \u2022 Amplification GCN \u2265 10 indicated\
  \ by FISH (confirmed centrally, slides or image from local laboratory will be confirmed\
  \ by the central pathologist) or NGS (confirmed either centrally or locally) \u2022\
  \ Overexpression indicated by IHC90+ (i.e. 3+ staining in \u2265 90% tumor cells\
  \ by central test, if local IHC results are available, image from local laboratory\
  \ will be confirmed by central pathologist. Despite the image submission, tissue\
  \ unstained slides should be sent to central laboratory for confirmation of MET\
  \ amplification or overexpression.)"
- 5. Treatment experience
- "1. Cohort 1: Anti-tumor treatment na\xEFve subject upon refusal to receive 1st\
  \ line standard of care, or not tolerated to 1st line standard of care, or progressed\
  \ after standard of care with no greater than 2 prior treatment regimens (neoadjuvant,\
  \ adjuvant, and maintenance therapies do not qualify as separate treatment regimens)."
- '2. Cohort 2: Progressed on prior the 1st line 3rd generation EGFR-TKI for the treatment
  of advanced/metastatic NSCLC'
- 6. At least one measurable lesion per response evaluation criteria in solid tumors
  (RECIST) 1.1
- '7. While on study treatment and for 6 months after the last dose of study treatment,
  a patient must:'
- 1. Not breast feed or be pregnant.
- 2. Not donate gametes (ie, eggs or sperm) or freeze for future use for the purpose
  of assisted reproduction.
- 3. Wear an external condom when engaging in any activity that allows for passage
  of ejaculate to another person.
- 4. If of childbearing potential
- "i. Have a negative highly sensitive (eg, beta-human chorionic gonadotropin \\[\u03B2\
  -hCG\\]) pregnancy test at screening and within 72 hours before the first dose of\
  \ study treatment, and agree to further pregnancy tests, ii. Practice at least 1\
  \ highly effective method of contraception; if oral contraceptives are used, a barrier\
  \ method of contraception must also be used."
- e. If a patient's partner is of childbearing potential, the participant must use
  a condom and partner of the participant must also be practicing a highly effective
  method of contraception. A vasectomized patient must still use a condom, but the
  partner is not required to use contraception.
- "8. Resolution of prior-therapy-related AEs (including immune-related AEs but excluding\
  \ alopecia) to \u2264 Grade 1 per CTCAE v 5.0, and no treatment for these AEs for\
  \ at least 2 weeks prior to the time of enrollment. Alopecia, sensory neuropathy\
  \ Grade \u2264 2, or other Grade \u2264 2 AEs not constituting a safety risk based\
  \ on investigator's judgment are acceptable."
- 9. Adequate organ function as indicated by laboratory values.
- 10. Submit tissue and blood specimens.
- <!-- -->
- '1. Cohort 1:'
- '1. All patients should submit tumor tissue/block collected from fresh biopsy or
  have available archival formalin-fixed, paraffin-embedded tumor tissue specimen.
  The archival tissue must be:'
- '* collected after progression from most recent prior systemic anti-cancer treatment,
  OR'
- '* If an archival tissue collected after progression to the most recent systemic
  anti-cancer treatment is not available, tissue samples from previous lines of treatment
  are acceptable.'
- For fresh biopsied sample, core needle biopsy is permitted. Samples from fine-needle
  aspiration (FNA) is not acceptable unless the result of MET exon 14 skipping from
  local testing is available.
- 2. All patients must submit blood samples.
- '2. Cohort 2:'
- 1. All patients should submit either fresh or archival tumor slides/block collected
  after progression from 1st line 3rd generation EGFR TKI. The archival tissue can
  be permitted ONLY IF it is collected after progression from 1st line 3rd generation
  EGFR TKI.
- 2. All patients should submit blood samples. 11. Able and willing to comply with
  the protocol and the restrictions and assessments therein.
- 'Exclude - Exclusion Criteria:'
- Exclude - 1. Previous severe hypersensitivity reaction to any component of study
  drug(s).
- Exclude - 2. Prior therapy
- Exclude - a. Previous treatment with c-MET inhibitors or hepatocyte growth factor
  (HGF)-targeting therapy.
- Exclude - b. For Cohort 2, prior chemotherapy for advanced, recurrent, or metastatic
  setting.
- 'Exclude - 3. Genetic analysis results:'
- 'Exclude - 1. Cohort 1: Existing genetic data from the patient''s tumor tissue showing
  known molecular alterations which would make them eligible for targeted therapies
  (e.g., EGFR mutations, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF
  mutation, RET alteration, and NTRK fusion, etc.).'
- 'Exclude - 2. Cohort 2: Patients with known molecular alterations that can''t benefit
  from study medication (e.g., EGFR mutation known to be associated with the resistance
  to 3rd generation EGFR TKIs, such as C797X or insertion 20, ALK rearrangements,
  KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion,
  etc.).'
- Exclude - 4. Chronic inflammatory liver condition. History or clinical evidence
  of any significant liver or biliary pathology including cirrhosis, infectious disease,
  inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis,
  primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract,
  spasm of sphincter of Oddi, biliary cyst or biliary atresia).
- Exclude - 5. Past medical history of Interstitial Lung Disease (ILD)/pneumonitis,
  drug-induced or radiation ILD/pneumonitis that required steroid treatment or other
  immune suppressive agents, or evidence of current symptomatic interstitial lung
  disease or unexplained pulmonary symptoms indicative of ILD such dyspnea, cough,
  or fever.
- Exclude - 6. Impairment of Gastrointestinal (GI) function or GI disease that may
  significantly alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled
  nausea, uncontrolled vomiting, uncontrolled diarrhea, or malabsorption syndrome)
- Exclude - 7. Prior organ or stem cell transplant.
- Exclude - 8. Known active infection with human immunodeficiency virus (HIV), human
  T-cell leukemia virus, type (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus
  (HCV), unless the patients fall into below categories (patients fall into one of
  the a, b, c category are eligible to participate)
- Exclude - 1. HIV
- "Exclude - \u2713 CD4+ cells \u2265 350 cells/\xB5L"
- "Exclude - \u2713 No history of AIDS"
- "Exclude - \u2713 No history of opportunistic infection in the past 12 months"
- Exclude - 2. HCV
- "Exclude - \u2713 Undetectable viral load (Participants positive for hepatitis C\
  \ antibody are eligible only if polymerase chain reaction is negative for hepatitis\
  \ C RNA)"
- "Exclude - 3. HBV \u2713 Concurrent HBV treatment and undetectable viral load (Participants\
  \ with a past or resolved hepatitis B infection defined as the presence of hepatitis\
  \ B core antibody \\[anti-HBc\\] and absence of hepatitis B surface antigen are\
  \ eligible)"
- Exclude - 9. Symptomatic ascites or pleural effusion, unless clinically stable for
  at least two weeks following treatment for these conditions (including therapeutic
  thoraco- or paracentesis).
- Exclude - 10. Known active central nervous system (CNS) primary tumor or metastases
  and/or carcinomatous meningitis. Patients with previously treated brain metastases
  may participate provided they are clinically stable for at least 4 weeks prior to
  first dose of study medication(s), have no evidence of new or enlarging brain metastases
  and are off steroids for at least 15 days prior to first dose of study medication(s).
- 'Exclude - 11. Presence or history of a malignant disease other than disease to
  be treated in current protocol that has been diagnosed and/or required therapy within
  the past 3 years. Exceptions to this exclusion include the following: completely
  resected basal cell and squamous cell skin cancers, indolent malignancies that currently
  do not require treatment, and completely resected carcinoma in situ of any type.'
- Exclude - 12. Active infection requiring therapy. However, subject with minor infections
  requiring oral antibiotics, (e.g., urinary tract infection, Upper respiratory tract
  infection, etc.) could be eligible based on investigator's judgement.
- Exclude - 13. Use of systemic corticosteroids \> 10 mg/day prednisone or equivalent
  within 30 days or other immunosuppressive drugs within 30 days prior to first drug
  administration.
- Exclude - 14. Patients receiving treatment with medications that meet one of the
  following criteria and that cannot be discontinued specified period prior to the
  start of treatment with study drug and for the duration of the study.
- 'Exclude - For Vabametkib (Wash-out: 1 week)'
- "Exclude - \u2022 Strong and moderate inhibitors/inducers of P-glycoprotein"
- "Exclude - \u2022 Strong and moderate inhibitors/inducers of CYP3A4"
- "Exclude - \u2022 Proton pump inhibitors (PPI)"
- "Exclude - \u2022 Potassium-competitive acid blockers For Lazertinib"
- Exclude - * Strong and moderate CYP3A4 inducers
- Exclude - * Medications possibly prolong QT interval or induce Torsades de Pointes
- Exclude - 15. Has received or will receive a live vaccine within 30 days prior to
  the first administration of study medication. Seasonal flu vaccine that does not
  contain live vaccine are permitted.
- Exclude - 16. Received an investigational product (except for EGFR TKI in Cohort
  2) or treated with an investigational device within 30 days prior to first study
  drug administration.
- "Exclude - 17. Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted\
  \ agents or tyrosine kinase inhibitors (except for EGFR TKI in Cohort 2) within\
  \ 2 weeks (4 weeks in case of thoracic radiotherapy to lung fields) or 5 half-lives\
  \ (whichever is longer) of the start of study treatment; immunotherapy/monoclonal\
  \ antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug\
  \ conjugates, or radioactive isotopes within 6 weeks of the start of study treatment;\
  \ 7-day washout is permitted for palliative radiation (i.e. limited field, \u2264\
  \ 14-day course of radiotherapy) to non-CNS lesions."
- Exclude - 18. History or clinical evidence of any surgical or medical condition
  which the investigator judges as likely to interfere with the results of the study
  or pose an additional risk in participating e.g., rapidly progressive or uncontrolled
  disease involving a major organ system-vascular, ophthalmologic, cardiac (clinically
  important abnormalities in rhythm, conduction or morphology of resting ECG, uncontrolled
  hypertension, uncontrolled symptomatic heart failure), pulmonary, gastrointestinal,
  gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or
  an immunodeficiency, or clinically significant active psychiatric or abuse disorders.
- Exclude - 19. Is a regular user (including "recreational use") of any illicit drugs
  or had a recent history (within the last year) of substance abuse (including alcohol).
- Exclude - 20. Patients with a corrected QT interval (using Fridericia's correction
  formula) (QTcF) of \> 470 msec.
- Exclude - 21. Any factors that increase the risk of QTc prolongation or risk of
  arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history
  of long QT syndrome, or unexplained sudden death under 40 years of age in first
  degree relatives or any concomitant medications known to prolong QT interval or
  induce Torsades de Pointes.
- Exclude - 22. Congestive heart failure (CHF), defined as New York Heart Association
  (NYHA) class III-IV or hospitalization for CHF (any NYHA class), within 6 months
  of randomization.
- Exclude - 23. An active or past medical history of pericarditis, pericardial effusion
  that is clinically unstable, or myocarditis. Pericardial effusion considered due
  to the disease under study is permitted if clinically stable at Screening.
- Exclude - 24. (for Cohort 2) Baseline LVEF either \<50% or below the lower limit
  of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram
  or MUGA scan.
- Exclude - 25. (for Cohort 2) Patients who have been receiving medications with potential
  for QT interval prolongation will be eligible only when the wash out period was
  finished.
short_title: To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile
  of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Abion Inc
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability
  and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance
  solid tumors with c-MET alterations as monotherapy.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Cohort 1: Vabametkib'
      arm_internal_id: 0
      arm_description: Subjects will receive vabametkib 800 mg, monotherapy, administered
        orally once daily in 21-day cycles
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Vabametkib'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Cohort 2: Lazertinib & Vabametkib'
      arm_internal_id: 1
      arm_description: 'Part 1 (Safety Run-in): Subjects will receive lazertinib 240
        mg in combination with one of three assigned dose levels of vabametkib, administered
        orally once daily in 21-day cycles


        Part 2 (Random Dose Optimization): A maximum of two vabametkib dose levels
        will be evaluated in this part. Patients will be randomized in 1:1 ratio to
        vabametkib dose level 1 (selected from Part 1) plus the determined dose of
        lazertinib or dose level 2 (selected from Part 1) plus the determined dose
        of lazertinib


        Part 3 (Randomized Clinical Trial): Patients will be randomized in 1:1 ratio
        to optimized vabametkib dose (selected from Part 2) plus lazertinib or Standard
        of Care (SOC) arm. SOC arm will be decided by the time of Part 3 initiation'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Vabametkib'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Lazertinib'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Advanced
          - Recurrent
          - Metastatic
          oncotree_primary_diagnosis: _SOLID_
      - and:
        - or:
          - genomic:
              hugo_symbol: MET
              variant_category: Mutation
        - or:
          - genomic:
              hugo_symbol: EGFR
              variant_category: Mutation
        - and:
          - genomic:
              hugo_symbol: EGFR
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: ALK
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: KRAS
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: ROS1
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: BRAF
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: RET
              variant_category: '!Mutation'
          - genomic:
              hugo_symbol: NTRK
              variant_category: '!Mutation'
